Tuberculosis is the leading cause of death from infectious disease.[@b0005] Although the number of tuberculosis cases decreased during the 20th century, the emergence of HIV and the incidence of multiple-drug resistance have increased the difficulty of treating many new cases.[@b0005], [@b0010] Despite efforts to improve the outcome of tuberculosis care, the discovery of new antibiotics against the causative agent *Mycobacterium tuberculosis* has been insufficient to eradicate the disease.[@b0015] New and more effective drugs with novel mechanisms of action are required to shorten treatment, improve patient adherence, and reduce the appearance of resistance.

*Mycobacterium tuberculosis* can adapt metabolically to host environments and can catabolize multiple carbon sources simultaneously.[@b0020] Fatty acids are the major carbon source available during infection,[@b0025] although carbohydrates, lipids, and carbon dioxide can also be utilized as carbon sources.[@b0030]

We recently reported the identification of a family of oxadiazoles **1**--**5** ([Fig. 1](#f0005){ref-type="fig"})[@b0035] from a whole cell screen against *M. tuberculosis* using butyrate as the carbon source. The compounds were active in medium containing butyrate, but not glucose and lacked mammalian cytotoxicity.[@b0035], [@b0040] The lack of cytotoxicity and the low molecular weight prompted us to undertake structure activity relationship (SAR) investigations around this series.Fig. 1Oxadiazoles previously identified from whole cell screening against *Mycobacterium tuberculosis,* adapted from Early et al.[@b0035]

Aryl-oxadiazoles, the common structural motif in compounds **1**--**5**, have been widely applied in medicinal chemistry for the development of new drugs. Compounds containing the 1,2,4- and 1,3,4-oxadiazole motif have been evaluated against a broad spectrum of pharmacological activities, with special attention to their properties as antimicrobial and antitubercular agents.[@b0045], [@b0050], [@b0055], [@b0060]

Synthetic methods for the preparation of differently functionalized 1,3,4-oxadiazoles have been recently reviewed.[@b0065] Compound 2 was resynthesized and compounds **13**--**18** and **24**--**41** were made in three steps by the method previously published for making compound **2**, starting from the corresponding hydrazide and then reacting the intermediate chloride with the appropriate secondary amine.[@b0035] Compounds **6**--**9** were prepared according to the representative procedure exemplified in [Scheme 1](#f0025){ref-type="fig"} for compound **8**. Hydrazide **8a** was coupled with carboxylic acid **8b** using EDC and HOBt to obtain the intermediate **8c**. Cyclodehydration of semicarbazide **8c** by refluxing with phosphoryl chloride yielded compound **8**.Scheme 1Synthesis of compound **8**. Reagents and conditions: (a) EDC, HOBt, DMF; (b) POCl~3~, 110 °C.

In order to prepare thiadiazole **10**, reaction of furan-2-carbohydrazide **10a** with chloroacetyl chloride in the presence of *N*-methylmorpholine produced the intermediate acylsemicarbazide **10b** ([Scheme 2](#f0030){ref-type="fig"}). Acylsemicarbazide **10b** was refluxed with Lawesson's reagent in THF to obtain the intermediate chloride **10c**. Chloride replacement by 2-chloro-6-fluorobenzylamine at reflux in the presence of DIPEA and sodium iodide generated the secondary amine **10d** which was treated with sodium hydride and methyl iodide to give compound **10**. Compounds **11**, **12** and **19** were prepared from the corresponding oxadiazole analogue to chloride **10c** by reaction with the appropriate primary amine followed by methylation.Scheme 2Synthesis of compound **10**. Reagents and conditions: (a) *N*-methylmorpholine, chloroacetyl chloride, CH~2~Cl~2~; (b) Lawesson's reagent, THF, reflux; (c) 2-Chloro-6-fluorobenzylamine, DIPEA, NaI, CH~3~CN, reflux; (d) MeI, NaH, DMF.

The synthesis of the oxadiazole **21** containing an ether group in the linker was achieved by cyclization of acylsemicarbazide **10b** using phosphoryl chloride to create **21a** followed by the reaction of the intermediate **21a** with (2-chloro-6-fluorophenyl)methanol ([Scheme 3](#f0035){ref-type="fig"}). Amide **22** was prepared from chloride **21a** in two steps, via **22a**. Substitution of chloride **21a** by methylamine followed by amide formation using 2-chloro-6-fluorobenzoic acid in the presence of HATU and triethylamine provided the amide **22** ([Scheme 3](#f0035){ref-type="fig"}). Compound **20** was prepared by reaction of intermediate **21a** with 2-chloro-6-fluorobenzylamine using DIPEA and sodium iodide.Scheme 3Synthesis of compounds **21** and **22**. Reagents and conditions: (a) phosphoryl chloride; (b) (2-Chloro-6-fluorophenyl)methanol, NaH, THF; (c) MeNH~2~, NaI, CH~3~CN, reflux; (d) 2-Chloro-6-fluorobenzoic acid, HATU, Et~3~N, DMF.

The synthesis of compound **23** utilized the three-step route shown in [Scheme 4](#f0040){ref-type="fig"}. Commercially available 1,3,4-oxadiazol-2-one **23a** was refluxed with 2-chloro-6-fluoro-phenethylamine **23b** in ethanol to obtain intermediate **23c** that was cyclized by heating with phosphoryl chloride. Methylation of secondary amine **23d** using methyl iodide in the presence of sodium hydride in DMF afforded compound **23**.Scheme 4Synthesis of compound **23**. Reagents and conditions: (a) EtOH, 100 °C; (b) POCl~3~, 110 °C; (c) MeI, NaH, DMF.

We began by evaluating mouse microsomal metabolism and thermodynamic solubility for aryl-oxadiazole hits from the screen ([Fig. 1](#f0005){ref-type="fig"}, [Table 1](#t0005){ref-type="table"}), and learned that these compounds were all highly metabolized, and solubility varied. We then focused our attention on the most potent hit from the screen, compound **1** (previously reported MIC was 0.4 ± 0.1 µM in butyrate medium)[@b0035] and synthesized compounds **6**--**9** ([Fig. 2](#f0010){ref-type="fig"}) to answer specific structure-activity questions. In order to compare 2-thienyl- with 2-furyl-oxadiazole, the thiophene ring in compound **1** was replaced with furan **6** ([Fig. 2](#f0010){ref-type="fig"}, [Table 2](#t0010){ref-type="table"}). These two compounds have comparable activity in butyrate medium (7H9-Ty-BT) ([Table 2](#t0010){ref-type="table"}). Replacements for 1-naphthyl in compound **1** were also examined, detecting that 2-naphthyl **7** was less potent while 5-benzodioxine **8** or phenyl **9** retained activity Compounds **6**--**9** showed neither activity under glucose conditions (7H9-Tw-OADC) nor cytotoxicity in Vero cells ([Table 2](#t0010){ref-type="table"}).Fig. 2SAR around compound **1**.Table 1Mouse microsomal metabolism, unbound intrinsic clearance[@b0070] and aqueous solubility for aryl-oxadiazoles from the screen.CpdMouse microsome (% metabolized in 30 min)Mouse microsome unbound intrinsic clearance (ml/min/kg)Aqueous solubility at pH 7.4 (mg/mL)clogP[a](#tblfn1){ref-type="table-fn"}**1**993310\<0.0013.9**2**9913500.0772.5**3**6519100.0054.4**4**951680\<0.0013.7**5**763320.0182.3[^1]Table 2Biological activity for compounds exploring SAR on the most potent screening hit.Cpd7H9-Ty-BT[a](#tblfn2){ref-type="table-fn"}^,^[b](#tblfn3){ref-type="table-fn"} MIC (μM)7H9-Tw-OADC[a](#tblfn2){ref-type="table-fn"}^,^[c](#tblfn4){ref-type="table-fn"} MIC (μM)Vero IC~50~ (μM)Mouse microsome (% metabolized)Aqueous solubility at pH 7.4 (mg/mL)clogP[d](#tblfn5){ref-type="table-fn"}**6**1.1 ± 0.9\>20\>100100\<0.0013.1**7**5.7 ± 0.2\>20\>100100\<0.0013.9**8**0.8 ± 0.2\>20\>100990.0772.6**9**1.1 ± 0.2\>2079990.0312.7[^2][^3][^4][^5]

Compound **1** ([Fig. 1](#f0005){ref-type="fig"}, [Table 1](#t0005){ref-type="table"}) and the analogs **6**--**9** ([Table 2](#t0010){ref-type="table"}) suffered from very high microsomal metabolism. Although aqueous solubility was low for the most lipophilic compounds **1**, **3**, **4**, **6** and **7**, a trend to improve solubility was observed when lowering calculated logP (clogP), as in compounds **2**, **5**, **8** and **9**.

The focus of SAR evaluation became improving solubility and metabolic stability while maintaining potency. With this goal, we explored the SAR around compound **2** ([Fig. 1](#f0005){ref-type="fig"}), which had a previously reported MIC of 0.8 ± 0.3 µM in butyrate medium[@b0035] based on the improved solubility with respect to compounds **1**, **3**--**5**. The 1,3,4-thiadiazole **10** ([Fig. 3](#f0015){ref-type="fig"}, [Table 3](#t0015){ref-type="table"}) was slightly less potent and less soluble than the 1,3,4-oxadiazole (**2**), so we continued the SAR evaluation using 1,3,4-oxadiazole as the heterocyclic core. Replacement of the furan ring in **2** by thiophene **11** or phenyl **12** led to equipotent compounds with similar solubility. The lack of both substituents at the *ortho*-positions, as in compounds **13**--**14**, or the presence of a single substituent, as in compound **15**, did not change the antimicrobial activity relative to compound **2**, suggesting that substitution at *ortho*-positions is not required for activity. Nevertheless, the lack of one or both substituents at the *ortho*-positions decreased clogP and significantly increased solubility. Compound **16**, having a fluoro group at the 4-position of the benzyl substituent, had similar potency in comparison to compound **12**. However, the trifluoromethyl group at 4-position in compounds **17** and **18** substantially decreased the activity with respect to compounds **11** and **12** and negatively impacted on solubility. Replacement of the benzyl group with a cyclohexylmethyl group as in compound **19** was also well tolerated. With respect to the linker, the *N*-methyl group in compound **2** appears important for activity. Replacement by the secondary amine **20** or oxygen **21** decreased the activity, while the tertiary amide **22** resulted in complete loss of activity. As expected, the lower lipophilicity of compounds **20**--**22** compared to compound **2** was beneficial for solubility. Compound **23**, with the nitrogen directly attached to the oxadiazole ring, reduced activity and the absence of a basic nitrogen resulted in reduced solubility. As previously seen, there was no or low cytotoxicity against Vero cells for compounds **10**--**23** ([Fig. 3](#f0015){ref-type="fig"}, [Table 3](#t0015){ref-type="table"}).Fig. 3Analogues of compound **2**. SAR on aromatic domains and linker.Table 3Biological activity for compounds exploring SAR on aromatic domains and linker.CpdRXYZ7H9-Ty-BT[a](#tblfn6){ref-type="table-fn"}^,^[b](#tblfn7){ref-type="table-fn"} MIC (μM)7H9-Tw-OADC[a](#tblfn6){ref-type="table-fn"}^,^[c](#tblfn8){ref-type="table-fn"} MIC (μM)Vero IC~50~ (μM)Mouse microsome (% metabolized)Aqueous solubility at pH 7.4 (mg/mL)clogP[d](#tblfn9){ref-type="table-fn"}**10**3.2 ± 0.5\>2075990.0203.3**11**2-Thiophenyl0.6 ± 0.2\>20\>1001000.123.1**12**Phenyl0.4 ± 0.2\>20\>1001000.0783.2**13**2-ThiophenylHH0.5 ± 0.1\>20\>100980.422.2**14**2-FuranylHH0.6 ± 0.2\>20\>100950.401.7**15**2-FuranylClH0.6 ± 0.2\>20981000.272.4**16**PhenylHF0.9 ± 0.03\>2097NDND2.4**17**2-ThiophenylHCF~3~6.8 ± 2.4\>2087980.0223.1**18**PhenylHCF~3~10.8 ± 3.3\>2080990.0093.2**19**0.7 ± 0.5\>20901000.0412.6**20**NH5.5 ± 0.4\>20\>100990.181.5**21**O6.0 ± 0.4\>20\>1001000.152.1**22**\>20\>20\>100950.641.7**23**4.0 ± 0.6\>2093990.0074.0[^6][^7][^8][^9]

Compound **3** ([Fig. 1](#f0005){ref-type="fig"}), which had a previously reported MIC of 2.2 ± 0.4 µM in butyrate medium[@b0035], is a structurally constrained analogue containing a 1,2,4-oxadiazole core linked to a 3-thiophene instead of the 2-thiophene. Compound **24** ([Fig. 4](#f0020){ref-type="fig"}), a hybrid structure between compounds **3** and **5** containing the tetrahydroquinoline piece and the 1,3,4-oxadiazole core, was active ([Table 4](#t0020){ref-type="table"}). A representative subset of tetrahydroquinoline compounds replacing the electron--rich thiophene by phenyl **25** or electron-deficient phenyls **26**, **27** was prepared. In this set, phenyl **25** failed to increase potency over **24** but, in contrast, 4-fluorophenyl **26** achieved a small improvement in activity and 4-trifluoromethylphenyl **27** retained potency. Interestingly, the tetrahydroisoquinoline regioisomers **28**--**31** were much less potent, showing that the site of fusion between the phenyl and the piperidine ring had a significant effect on activity. The clear preference for the tetrahydroquinoline orientation also indicates that the basicity of the nitrogen is not critical for maintaining potency although it influences solubility. 1,4-Benzoxazines **32**--**35** were less potent than the corresponding tetrahydroquinolines **24**--**27**. The size of the heterocyclic ring also impacted the activity. Indolines **36**--**37** lowered potency while isoindolines **38**--**39** lowered it even more, as expected based on the position of the nitrogen atom. When a nitrogen atom is part of the 2-phenylpyrrolidine ring as in **40**--**41**, compounds displayed minimal activity. As expected, compounds **24**--**41** were not cytotoxic and did not have activity against *M. tuberculosis* in medium containing glucose ([Fig. 4](#f0020){ref-type="fig"}, [Table 4](#t0020){ref-type="table"}).Fig. 4SAR around compound **24**, a hybrid structure between compounds **3** and **5**.Table 4Biological activity for compounds exploring SAR of the tetrahydroquinoline with the 1,3,4-oxadiazole.CpdR7H9-Ty-BT[a](#tblfn10){ref-type="table-fn"}^,^[b](#tblfn11){ref-type="table-fn"} MIC (μM)7H9-Tw-OADC[a](#tblfn10){ref-type="table-fn"}^,^[c](#tblfn12){ref-type="table-fn"} MIC (μM)Vero IC~50~ (μM)Mouse microsome (% metabolized)Aqueous solubility at pH 7.4 (mg/mL)clogP[d](#tblfn13){ref-type="table-fn"}**24**2-Thiophenyl0.8 ± 0.5\>20\>100970.0053.2**25**Phenyl1.7 ± 0.1\>20\>1001000.0033.5**26**4-F-Phenyl0.2 ± 0.1\>20\>100100\<0.0023.5**27**4-CF~3~-Phenyl0.7 ± 0.3\>20\>10087\<0.0024.2**28**2-Thiophenyl3.7 ± 0.3\>20\>100990.0542.5**29**Phenyl7.7 ± 0.8\>20\>100990.0512.6**30**4-F-Phenyl4.7 ± 1.3\>20\>100800.0402.8**31**4-CF~3~-Phenyl\>20\>20\>100ND\<0.0023.5**32**2-Thiophenyl1.8 ± 0.6\>20\>100990.0332.6**33**Phenyl2.8 ± 1.7\>20\>100990.0282.7**34**4-F-Phenyl1.8 ± 0.4\>20\>10098\<0.0022.9**35**4-CF~3~-Phenyl8.3 ± 1.7\>208595\<0.0023.6**36**2-Thiophenyl2.1 ± 0.1\>20\>100990.0382.8**37**Phenyl2.3 ± 0.9\>20\>100990.0212.9**38**2-Thiophenyl6.7 ± 1.7\>20\>100990.0122.0**39**Phenyl7.5 ± 3.5\>20\>100980.0202.1**40**2-Thiophenyl9.9 ± 2.1\>20501000.0502.8**41**Phenyl8.3 ± 1.4\>20\>100990.0342.9[^10][^11][^12][^13]

All the compounds we synthesized suffered from poor microsomal stability in mice ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}) and rats (data not shown). One of the first strategies to increase metabolic stability is to reduce the overall lipophilicity. However, a correlation between microsomal metabolism and clogP could not be observed as a few compounds that lowered calculated lipophilicity did not reduce oxidative metabolism ([Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}). On the positive side, lipophilicity apparently plays a secondary role in potency because correlation between clogP and activity was not observed ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}).

To further investigate the impact of microsomal metabolism on clearance, three of the structurally different screening hits were selected for mouse pharmacokinetic (PK) studies ([Table 5](#t0025){ref-type="table"}). The PK evaluation of **1**, **2** and **3** was performed after intravenous (1 mg/kg) and oral (10 mg/kg) administration to mice. In order to confirm that clearance was due to oxidative metabolism, compound **2** was co-administered with 1-aminobenzotriazole (ABT), a non-selective cytochrome P450 inhibitor.[@b0075] Compound **2** was rapidly eliminated from the body, but clearance decreased significantly when co-administered with ABT, demonstrating that the high clearance was due to CYP-mediated metabolic oxidation. This result is consistent with the very low microsomal stability. Oral exposure was low and increased \>10 fold when co-administered with ABT, proving that first pass metabolism limits exposure. Blood clearance for compound **1** was low but oral exposure was much lower than expected, suggesting solubility-limited drug absorption. Compound **3** had moderate clearance and the very low oral exposure may be due to first-pass metabolism and/or solubility-limited absorption.Table 5Mouse PK parameters for compounds **1**, **2**, and **3** after oral and intravenous administration.Intravenous administration (1 mg/kg)Oral administration (10 mg/kg)CpdClint,u (mL/min/kg)AUC~0--24~ (ng·h/mL)Cl (mL/min/kg)AUC,u~0--24~ (ng·h/mL)CL,u (mL/min/kg)V~dss~ (L/kg)t~1/2~ (h)AUC~0--24~ (ng·h/mL)Cmax (ng/ml)Tmax (h)Cmax,u (ng/ml)133102900193217270.91.231192.750.22135030056374551.10.348310.253.82[a](#tblfn14){ref-type="table-fn"}1350270012332981.31.723008880.661093191043041627336.32.91090.250.1[^14][^15]

We tried several things to improve aqueous solubility for this series. As a general trend, the presence of a basic nitrogen in the linker increased solubility, and solubility was further increased with additional reduction in lipophilicity as seen in [Table 3](#t0015){ref-type="table"}. We also explored how compounds with basic character could benefit from forming salts to optimize solubility and biopharmaceutical properties. As expected, compound **2** as free base had much lower solubility (0.049 mg/mL at pH = 6 and 0.077 mg/mL at pH = 7.4) than the maleate salt (0.687 mg/mL at pH = 6 and 0.717 mg/mL at pH = 7.4). Based on this result, salt formation should be considered the preferred approach to increase aqueous solubility for this structural class containing a basic center.

In summary, we completed the SAR evaluation of a 1,3,4-oxadiazole series of compounds with activity against *M. tuberculosis*. Compounds had good anti-tubercular activity when tested against bacteria utilizing butyrate as a carbon source, but not with glucose as a carbon source. Although this series will require optimization of molecular properties to improve oral exposure, several 1,3,4-oxadiazoles are valuable tools that will facilitate further study including target identification.
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[^1]: clogP values are calculated from BioByte software.

[^2]: Results are average ± standard deviation for at least 2 runs.

[^3]: Growth medium with butyrate as the primary carbon source.

[^4]: Growth medium with glucose as the primary carbon source.

[^5]: clogP values are calculated from BioByte software.

[^6]: Results are average ± standard deviation for at least 2 runs.

[^7]: Growth medium with butyrate as the primary carbon source.

[^8]: Growth medium with glucose as the primary carbon source.

[^9]: clogP values are calculated from BioByte software.

[^10]: Results are average ± standard deviation for at least 2 runs.

[^11]: Growth medium with butyrate as the primary carbon source.

[^12]: Growth medium with glucose as the primary carbon source.

[^13]: clogP values are calculated from BioByte software.

[^14]: Cl, clearance; Cl,u, Unbound clearance (Total Cl/unbound fraction in plasma); Vd, volume of distribution; t~1/2~, plasma elimination half-life; AUC, area under the curve AUC,u, unbound area under the curve (total AUC x unbound fraction in plasma). See [supplementary information](#s0015){ref-type="sec"} for the unbound fraction in plasma. For unbound concentration calculations, blood:plasma ratio was assumed to be 1.

[^15]: Compound **2** was co-administered with ABT (100 mg/kg, 1 h pre-dose), a non-selective CYP-P~450~ inhibitor.
